The Difference Between Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of B-cells or T-cells. Hodgkin’s lymphoma is marked by the presence of special type of cell called a Reed-Sternberg cell.

But there are many other differences between Non-Hodgkin’s and Hodgkin’s lymphomas; they involve, among other things, the treatment options, survival rate, incidence, and symptoms.

Age

Hodgkin’s Lymphoma typically occurs in younger patients, age 15 to 24, and older patients over 60.

Non-Hodgkin’s Lymphoma is rare in young patients. Most diagnoses are made in patients over 60 years old.

Incidence

Hodgkin’s Lymphoma accounts for less than 1% of all cancers diagnosed in the U.S. per year. This represents about 15% of all lymphomas.

Non-Hodgkin’s Lymphoma accounts for about 4% of all cancers diagnosed in the U.S. per year. This represents around 85% of all lymphomas.

For both types of lymphomas, more men are affected than women.

Location

Hodgkin’s Lymphoma usually starts in the lymph nodes in the neck. However, it can spread to other lymph node groups, the lungs, spleen, and bone marrow, depending on the stage.

Non-Hodgkin’s Lymphoma can start in a variety of locations depending on the type of cancer and cells affected.

Symptoms

Hodgkin’s Lymphoma often presents with fever and night sweats, which are Grade B symptoms.

Non-Hodgkin’s Lymphoma is less likely to present with Grade B symptoms.

Progression

Hodgkin’s Lymphoma progresses in an orderly fashion between lymph groups, and is often caught before Stage IV.

Non-Hodgkin’s Lymphomas are less orderly, sometimes more aggressive, and are more likely to be caught in advanced stages.

Outcome

Hodgkin’s Lymphoma is considered one of the most treatable cancers. With the discovery of new chemotherapy and radiation protocols, survival in the early years is over 90%.

Non-Hodgkin’s Lymphoma has a lower survival rate in most cases, though it varies by type. Some diseases have survival rates over 80%, though some of the more aggressive and rare types have lower rates.

Related Articles

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap